Author: Dai, Jian-Ping; Wang, Qian-Wen; Su, Yun; Gu, Li-Ming; Deng, Hui-Xiong; Chen, Xiao-Xuan; Li, Wei-Zhong; Li, Kang-Sheng
Title: Oxymatrine Inhibits Influenza A Virus Replication and Inflammation via TLR4, p38 MAPK and NF-κB Pathways Cord-id: wr0eg4re Document date: 2018_3_23
ID: wr0eg4re
Snippet: Oxymatrine (OMT) is a strong immunosuppressive agent that has been used in the clinic for many years. In the present study, by using plaque inhibition, luciferase reporter plasmids, qRT-PCR, western blotting, and ELISA assays, we have investigated the effect and mechanism of OMT on influenza A virus (IAV) replication and IAV-induced inflammation in vitro and in vivo. The results showed that OMT had excellent anti-IAV activity on eight IAV strains in vitro. OMT could significantly decrease the pr
Document: Oxymatrine (OMT) is a strong immunosuppressive agent that has been used in the clinic for many years. In the present study, by using plaque inhibition, luciferase reporter plasmids, qRT-PCR, western blotting, and ELISA assays, we have investigated the effect and mechanism of OMT on influenza A virus (IAV) replication and IAV-induced inflammation in vitro and in vivo. The results showed that OMT had excellent anti-IAV activity on eight IAV strains in vitro. OMT could significantly decrease the promoter activity of TLR3, TLR4, TLR7, MyD88, and TRAF6 genes, inhibit IAV-induced activations of Akt, ERK1/2, p38 MAPK, and NF-κB pathways, and suppress the expressions of inflammatory cytokines and MMP-2/-9. Activators of TLR4, p38 MAPK and NF-κB pathways could significantly antagonize the anti-IAV activity of OMT in vitro, including IAV replication and IAV-induced cytopathogenic effect (CPE). Furthermore, OMT could reduce the loss of body weight, significantly increase the survival rate of IAV-infected mice, decrease the lung index, pulmonary inflammation and lung viral titter, and improve pulmonary histopathological changes. In conclusion, OMT possesses anti-IAV and anti-inflammatory activities, the mechanism of action may be linked to its ability to inhibit IAV-induced activations of TLR4, p38 MAPK, and NF-κB pathways.
Search related documents:
Co phrase search for related documents- active compound and acute ards respiratory distress syndrome: 1, 2
- active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- active compound and addition time: 1, 2, 3
- active compound and addition time assay: 1
- active compound and low concentration: 1
- active compound and lung injury: 1, 2, 3, 4
- acute ali lung injury and low concentration: 1
- acute ali lung injury and luciferase activity: 1, 2
- acute ali lung injury and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8
- acute ali lung injury and lung homogenate: 1
- acute ali lung injury and lung index: 1, 2, 3
- acute ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- acute ali lung injury and lung right: 1
- acute ali lung injury and lung wet weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute ali lung injury lead and lung injury: 1, 2, 3
- acute ali lung injury lead and lung right: 1
- acute respiratory syndrome and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute respiratory syndrome and addition time assay: 1, 2, 3, 4
- acute respiratory syndrome and loss labored breathing: 1, 2
Co phrase search for related documents, hyperlinks ordered by date